ARTICLE | Emerging Company Profile
Anocca: Standardizing TCR cell therapy design
Sweden’s Anocca is creating libraries of engineered human cells that enable standardized, automated TCR target discovery and characterization
December 1, 2021 11:32 PM UTC
Anocca is using engineered human cells to recapitulate the T cell immune system ex vivo, eliminating the person-to-person variability in working with primary T cells from patients, to create standardized, scalable TCR-modified T cell therapies.
Anocca AB CEO Reagan Jarvis, a biochemist and the Swedish company’s scientific founder, was working on T cells when he became frustrated at the lack of methods for finding and characterizing TCRs or identifying HLA-restricted antigens. ...